DE60017733D1 - Verwendung von riluzol zur behandlung multipler sklerose - Google Patents

Verwendung von riluzol zur behandlung multipler sklerose

Info

Publication number
DE60017733D1
DE60017733D1 DE60017733T DE60017733T DE60017733D1 DE 60017733 D1 DE60017733 D1 DE 60017733D1 DE 60017733 T DE60017733 T DE 60017733T DE 60017733 T DE60017733 T DE 60017733T DE 60017733 D1 DE60017733 D1 DE 60017733D1
Authority
DE
Germany
Prior art keywords
treatment
multiple sclerosis
riluzol
benzothiazolamine
riluzole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017733T
Other languages
English (en)
Other versions
DE60017733T2 (de
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Original Assignee
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging voor Christelijk Wetenschappelijk Onderwijs
Application granted granted Critical
Publication of DE60017733D1 publication Critical patent/DE60017733D1/de
Publication of DE60017733T2 publication Critical patent/DE60017733T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60017733T 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose Expired - Lifetime DE60017733T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
US174328P 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
DE60017733D1 true DE60017733D1 (de) 2005-03-03
DE60017733T2 DE60017733T2 (de) 2006-01-12

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017733T Expired - Lifetime DE60017733T2 (de) 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose

Country Status (11)

Country Link
EP (2) EP1187612B1 (de)
JP (1) JP2003522121A (de)
AT (2) ATE287713T1 (de)
AU (1) AU777537B2 (de)
CA (1) CA2375874A1 (de)
DE (1) DE60017733T2 (de)
ES (1) ES2235896T3 (de)
NZ (1) NZ515685A (de)
PT (1) PT1187612E (de)
SI (1) SI1187612T1 (de)
WO (1) WO2000074676A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (de) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Wässrige Riluzol-Suspensionen
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
WO2016081466A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
CN107205986A (zh) 2014-11-26 2017-09-26 美迪诺亚公司 异丁司特和利鲁唑的组合及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
ES2206604T3 (es) * 1995-11-15 2004-05-16 Yamanouchi Pharmaceutical Co., Ltd. Inhibidores de la neurotoxicidad del acido kainico y derivados de la piridotiazina.
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose

Also Published As

Publication number Publication date
ATE287713T1 (de) 2005-02-15
AU777537B2 (en) 2004-10-21
CA2375874A1 (en) 2000-12-14
EP1552831B1 (de) 2009-01-07
PT1187612E (pt) 2005-05-31
ES2235896T3 (es) 2005-07-16
EP1187612B1 (de) 2005-01-26
WO2000074676A1 (en) 2000-12-14
EP1187612A1 (de) 2002-03-20
JP2003522121A (ja) 2003-07-22
DE60017733T2 (de) 2006-01-12
SI1187612T1 (en) 2005-06-30
NZ515685A (en) 2002-12-20
AU5421900A (en) 2000-12-28
ATE419851T1 (de) 2009-01-15
EP1552831A1 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60143061D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60226855D1 (de) Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE60017733D1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE60041365D1 (de) Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition